This $197,400 federal Project Grant awarded on February 15, 2025 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support the development of patient-derived central nervous system (CNS) metastasis models with STK11 inactivation for drug discovery at The Trustees of Columbia University in the City of New York. This research aims to advance the understanding and treatment of CNS metastases, an area of significant unmet medical need for military service members and the broader population. The project will run through February 14, 2026 and leverage Columbia University's expertise in biomedical research, medical product development, and collaborations with other academic institutions and industry partners.
Generated 3/4/25, 6:15 AM